How to treat Lung cancer?

['مڠهادڤي لاڤورن اين']

چارا ممباچ بسرڠ paru-paru؟

ڤلاجرن اونتوق كسرن ريهق برتوكر دڠن ببراڤ فاكتور، ترماسوق ڤرجواڠن كسرن، جنيس كسرن ريهق، دان كصيحتن عموم مريک.

ببراڤ ڤيليهن ڤلاجرن يڠ باڽق ترماسوق:

1. Operasi: اين غالباً درمان ترجيح داده شده براي سرطان ريه در مرحله اوليه است.

ڤڠاجر مڠحذف تومور دان سابوه باڬين كيت يڠ سليم دڤرتڠهڽ.

2. Terapi radiasi: radiasi bertenaga tinggi digunakan untuk membunuh sel kanker dan mengecilkan tumor.

دا يڠ دڬوناكن سولو اتاو دڠن ڤڠاوسن لاين.

3. كيموتراپي: ڤڠڬوناءن اين مڠڬوناكن دوا اونتوق ممڤوڽاءي سيل-سيل كينسر.

ڽن بوليه دڤرتودوهكن دالم ڤڠڬوناان انتراۏينوس اتاو اورال، ڠن بياسا دڬوناكن دڠن ڤڠڬوناان لاين.

4. terapi yang ditargetkan: terapi ini menargetkan gen atau protein tertentu yang berkontribusi pada pertumbuhan dan kelangsungan hidup sel kanker.

ڽن rancak digunakan untuk kanker paru-paru lanjutan atau metastatik.

5. Immunotherapy: ڤلاجرن اين ممڤوڽاءي سيستم imun اونتوق ممڤرتاهنکن دان مڠهاجمن سيل-سيل kanser.

ڽن rancak digunakan untuk kanker paru-paru lanjutan atau metastatik.

6. Terapi fotodinamik: ڤڠڬوناان اين مڠڬوناكن دوا يڠ دأكتيفاسي اوليه ڤڠڬوناان ڤڠوروسن اونتوق ممڤو ماتي سيل-سيل كسر.

بياساڽ دڬوناكن اونتوق كسرن paru-paru tahap awal.

7. Terapi Proton: اين اداله ساتو جوره ترڤي رادياسي يڠ مڠڬوناكن proton سلاين x-ray اونتوق ممبري رادياسي ك تومور.

بياساڽ دڬوناكن اونتوق كسرن paru-paru tahap awal.

8. Ujian klinis: Pasien mungkin layak untuk berpartisipasi dalam uji klinis pengujian pengobatan baru atau kombinasi pengobatan.

اي ڤنتيڠ اونتوق منچاري ڤيليهن ڤلاجرن يڠ باءيق دڠن ڤيمڤينن كصيحتن، كران ڤلن ڤلاجرن يڠ لبيه ايكسيفيكتيف اكن برتوكر دڠن كحالاتن خاص اورڠ.

['ريفرنس']

PubMed/Medline https://www.nlm.nih.gov/databases/download/pubmed_medline.html

RefinedWeb https://arxiv.org/abs/2306.01116

Chen JH, Wu J, Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Signal Transduct Target Ther. , 4 (): 61.

Furuse K: [Photodynamic therapy of centrally located early-stage lung cancer]. Gan To Kagaku Ryoho. 1996, 23 (1): 27-30.

Gálffy G: [From rare mutations to classical ones, inhibition of signaling pathways in non-small cell lung cancer]. Magy Onkol. 2020, 64 (3): 196-204.

Magalhães M, Alvarez-Lorenzo C, Concheiro A, Figueiras A, Santos AC, Veiga F: RNAi-based therapeutics for lung cancer: biomarkers, microRNAs, and nanocarriers. Expert Opin Drug Deliv. 2018, 15 (10): 965-982.

Kataoka M, Fujiwara T, Tanaka N: [Gene therapy for lung cancer]. Nihon Geka Gakkai Zasshi. 2002, 103 (2): 244-9.

Jin C, Yang B: A Case of Delayed Diagnostic Pulmonary Tuberculosis during Targeted Therapy in an EGFR Mutant Non-Small Cell Lung Cancer Patient. Case Rep Oncol. , 14 (1): 659-663.

Wang Y, Liu Q, Chen H, You J, Peng B, Cao F, Zhang X, Chen Q, Uzan G, Xu L, Zhang D: Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance. Anticancer Drugs. 2018, 29 (8): 748-755.

['ڤڠهادڤن: ميديك']

['ويب سايت اين دبريكن اونتوق ڤڠاجرن دان معلومت سهيڠڬ دان تيدق ممڤوڽاءي نصيحت ميديكل اتاو ڤرخدمتن ڤروفيسيونل.']

['معلومت يڠ دبريكن تيدق بوليه دڬوناكن اونتوق ممڤوڽاءي اتاو ممباوا ڤروبليم كصيحتن اتاو كمرضن، دان اورڠ-اورڠ يڠ ممڤوڽاءي نصيحت ميديكل ڤرسوداران بوليه مڠيكوت دوكتور يڠ مڠيكوت.']

['سوده دتنتوكن، jaring saraf يڠ ممبنتو جواڤن كڤد سوألن، تيدق ساڠت ڤاليڠ ڤاليڠ ڤاليڠ ڤاليڠ ڤاليڠ كتيک دتڠكڤ كڤد كونتينن نوميريک. سڤرتي، ڤندودوق اورڠ يڠ دڤرچاياڬوسكن دڠن كمرڬانن خاص.']

['Slalu seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Jika anda pikir anda mungkin mengalami keadaan darurat medis, hubungi 911 atau pergi ke ruang gawat darurat terdekat segera. Tidak ada hubungan dokter-pasien yang dibuat oleh situs web ini atau penggunaannya. BioMedLib maupun karyawannya, maupun kontributor situs web ini, tidak membuat representasi apapun, secara eksplisit atau implisit, sehubungan dengan informasi yang disediakan di sini atau penggunaannya. BioMedLib tidak akan memberikan jaminan, baik secara eksplisit maupun implisit, sehubungan dengan informasi yang disediakan di sini atau penggunaannya. BioMedLib tidak akan memberikan jaminan, baik secara eksplisit maupun implisit, sehubungan dengan informasi yang disediakan di sini atau penggunaannya. BioMedLib tidak akan memberikan jaminan, baik secara eksplisit maupun implisit, sehubungan dengan informasi yang disediakan di sini atau penggunaannya.']

['ڤڠهادڤن: حق ڤنوليس']

['Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) ممبري ڤڠاجرن اونتوق ڤميمڤين حق ڤنوليس يڠ مڠڬنتيكن بهاوا ماتريال يڠ دڤرچايا?? ي د انتارنيت مڠڬوناكن حقڽ دالم ڤرلمباڬان حق ڤنوليس اميريكا.']

['اڤابيلا ديري مڠڬنتيكن دڠن كصيحتن يڠ باءيق بهاوا ستياڤ كونتين اتاو ماتريال يڠ دڤاوڤونكن دڠن ڤڠڬوناان ويب اتاو ڤرخدمتن ديري مڠڬوناكن حق ڤنوليسن ديري، ديري (اتاو اڬين ديري) موڠكين مڠوروسكن كيت ساتو كپاتا ن مڠمبيل ستياڤ كونتين اتاو ماتريال دڤاوڤون اتاو كلوارڬ كيت.']

['ڤڠاجرن هاروس دجوال دڠن توليسن ملالوءي ايميل (تڠه سيكشن "Kontakt" اونتوق ايديريس ايميل)']

['DMCA ممرلوكن ڤڠاجرن ڤڠهيناان حق ڤنوليسن ترماسوق معلومت يڠ منوروت: (1) ڤنوليسن كراجا?? ن حق ڤنوليسن يڠ منجادي موضوع ڤڠهيناان ترماسوق معلومت (2) ڤنوليسن كونتينن يڠ ترماسوق ڤڠهيناان دان معلومت يڠ ممڤرلوكن كيت منچاري معلومت (3) معلومت ڤڠاتوهن كيت ترماسوق ايدريس، نومبر تيليفون دان ايدريس ايميل (4) كپاتا?? ن كيت يڠ ممڤرلوكن كڤد كيت كران كيت برهارڤ ڤڠهيناان يڠ دڤنوليسكن تيدق دأوتوريساسي اوليه ڤملكن حق ڤنوليسن اتاو اڬينڽ اتاو اوليه ڤڠڬونا?? ن ايستري.']

['(5) pernyataan awak, ditandatangani di bawah hukuman sumpah palsu, bahwa informasi dalam pemberitahuan adalah akurat dan awak memiliki wewenang untuk menegakkan hak cipta yang diklaim dilanggar; ']

['ڠن (6) ساتو ڤنوليسن فيزيک اتاو ايليکترونيک دري ڤميمڤين حق اوڤاي اتاو سأورڠ يڠ دأذنکن اونتوق مڠݢوناکن ڤميمڤين حق اوڤاي. ']

['كران تيدق ممڤوڽاءي سموا معلومت يڠ دڤرتوان اكن ممباوا كڤد ڤڠڬوناان كڤد كڤدأنن.']

['ڤرتوبوهن']

['Tulung kirimi kami email dengan pertanyaan/usulan apapun.']

How to treat lung cancer?

The treatment for lung cancer depends on several factors, including the stage of the cancer, the type of lung cancer, and the patient's overall health.

Some common treatment options include:

1. Surgery: This is often the preferred treatment for early-stage lung cancer.

The surgeon removes the tumor and a small portion of healthy tissue around it.

2. Radiation therapy: High-energy radiation is used to kill cancer cells and shrink tumors.

It can be used alone or in combination with other treatments.

3. Chemotherapy: This treatment uses drugs to kill cancer cells.

It can be given intravenously or or orally, and is often used in combination with other treatments.

4. Targeted therapy: This treatment targets specific genes or proteins that contribute to the growth and survival of cancer cells.

It is often used for advanced or metastatic lung cancer.

5. Immunotherapy: This treatment helps the immune system recognize and attack cancer cells.

It is often used for advanced or metastatic lung cancer.

6. Photodynamic therapy: This treatment uses a light-activated drug to kill cancer cells.

It is often used for early-stage lung cancer.

7. Proton therapy: This is a type of radiation therapy that uses protons instead of x-rays to deliver radiation to the tumor.

It is often used for early-stage lung cancer.

8. Clinical trials: Patients may be eligible to participate in clinical trials testing new treatments or combinations of treatments.

It is important to discuss the best treatment options with a healthcare team, as the most effective treatment plan will depend on the individual's specific situation.

Disclaimer: medical

This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.

The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.

Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.

Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.

Disclaimer: copyright

The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.